Back
ESC2025 Premium Access

Acoramidis leads to clinically meaningful improvements from baseline in NT-proBNP and 6-minute walk distance in patients with transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM

Session: Treatment of transthyretin amyloidosis
Topic: Infiltrative Myocardial Disease
Speaker: Doctor F. Cappelli (Florence, IT)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Francesco Cappelli

Careggi University Hospital (AOUC), Florence (Italy)
5 presentations
2 followers

7 more presentations in this session

Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis

Speaker: Doctor V. Castiglione (Pisa, IT)

Access
Abstract
Slides
Video
Like
Thumbnail

Optimizing treatment strategies for transthyretin amyloid cardiomyopathy: a comprehensive Bayesian network meta-analysis of disease-specific therapies

Speaker: Doctor M. Rahman (Flushing, US)

Access
Abstract
Slides
Video
Like
Thumbnail

Diagnostic, therapeutic and prognostic implications of carpal tunnel syndrome and spinal stenosis in wild-type transthyretin cardiac amyloidosis.

Speaker: Doctor P. Debonnaire (Brugge, BE)

Access
Abstract
Slides
Video
Like
Thumbnail

Effects of targeted transthyretin amyloid cardiomyopathy treatments on clinical outcomes a meta-analysis

Speaker: Doctor T. Tsampras (Athens, GR)

Access
Abstract
Slides
Video
Like
Thumbnail

Which patients did recent trials in transthyretin amyloid cardiomyopathy select? - insights from a prospective patient registry

Speaker: Doctor L. Schmid (Vienna, AT)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Treatment of transthyretin amyloidosis

Speakers: Doctor F. Cappelli, Doctor V. Castiglione, Doctor M. Rahman, Doctor P. Debonnaire, Doctor T. Tsampras...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources